Literature DB >> 14663034

A CAV3 microdeletion differentially affects skeletal muscle and myocardium.

R Cagliani1, N Bresolin, A Prelle, A Gallanti, F Fortunato, M Sironi, P Ciscato, G Fagiolari, S Bonato, S Galbiati, S Corti, C Lamperti, M Moggio, G P Comi.   

Abstract

BACKGROUND: Caveolin-3 is the muscle-specific protein product of the caveolin gene family and an integral membrane component of caveolae. Mutations in the gene encoding caveolin-3 (CAV3) underlie four distinct disorders of skeletal muscle: the autosomal dominant form of limb-girdle muscular dystrophy type 1C (LGMD-1C), rippling muscle disease (RMD), sporadic and familial forms of hyperCKemia, and distal myopathy.
OBJECTIVE: To characterize a multigenerational Italian family affected by an autosomal dominant myopathic disorder and to assess the expression of caveolin-3, dystrophin, dystrophin-associated glycoproteins, and neuronal nitric oxide synthase in the myocardium of an affected patient.
METHODS: Clinical analysis involved 15 family members. Skeletal muscle expression of sarcolemmal proteins was evaluated by immunohistochemistry and western blot analysis in three affected individuals. Caveolar structures were analyzed through electron microscopy in muscle biopsies and in one heart biopsy.
RESULTS: CAV3 genetic analysis showed a heterozygous 3-bp microdeletion (328-330del) in affected individuals, resulting in the loss of a phenylalanine (Phe97del) in the transmembrane domain. In the skeletal muscle, the mutation was associated with severe caveolin-3 deficiency and caveolar disorganization, whereas the expression of the other analyzed muscle proteins was unaltered. Remarkably, caveolin-3 was expressed in myocardium at a level corresponding to about 60% of that of control individuals and was correctly localized at the myocardial cell membranes, with preservation of cardiac myofiber caveolar structures. Clinical analysis revealed the concomitant presence in this family of the following phenotypes: RMD, LGMD, and hyperCKemia.
CONCLUSIONS: Intrafamilial phenotypic heterogeneity is associated with caveolin-3 Phe97 microdeletion. The molecular network interacting with caveolin-3 in skeletal muscle and heart may differ.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663034     DOI: 10.1212/01.wnl.0000097320.35982.03

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Expression of NTPDase1 and caveolins in human cardiovascular disease.

Authors:  Agnes Kittel; Anna L Kiss; Nándor Müllner; Ida Matkó; Beáta Sperlágh
Journal:  Histochem Cell Biol       Date:  2005-07-19       Impact factor: 4.304

Review 2.  Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.

Authors:  Louise R Rodino-Klapac; Amanda M Haidet; Janaiah Kota; Chalonda Handy; Brian K Kaspar; Jerry R Mendell
Journal:  Muscle Nerve       Date:  2009-03       Impact factor: 3.217

Review 3.  Caveolinopathies: from the biology of caveolin-3 to human diseases.

Authors:  Elisabetta Gazzerro; Federica Sotgia; Claudio Bruno; Michael P Lisanti; Carlo Minetti
Journal:  Eur J Hum Genet       Date:  2009-07-08       Impact factor: 4.246

Review 4.  Sudden cardiac death: focus on the genetics of channelopathies and cardiomyopathies.

Authors:  Simona Magi; Vincenzo Lariccia; Marta Maiolino; Salvatore Amoroso; Santo Gratteri
Journal:  J Biomed Sci       Date:  2017-08-15       Impact factor: 8.410

Review 5.  A Role for Caveolin-3 in the Pathogenesis of Muscular Dystrophies.

Authors:  Bhola Shankar Pradhan; Tomasz J Prószyński
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

6.  A novel 1-bp deletion variant in DAG1 in Japanese familial asymptomatic hyper-CK-emia.

Authors:  Luoming Fan; Shiroh Miura; Tomofumi Shimojo; Hirotoshi Sugino; Ryuta Fujioka; Hiroki Shibata
Journal:  Hum Genome Var       Date:  2022-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.